Report cover image

Global Novel Oral AntiCoagulants (NOAC) Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 205 Pages
SKU # APRC20280662

Description

Summary

According to APO Research, the global Novel Oral AntiCoagulants (NOAC) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Novel Oral AntiCoagulants (NOAC) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Novel Oral AntiCoagulants (NOAC) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Novel Oral AntiCoagulants (NOAC) market include Armatheon, Aspen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Daiichi Sankyo and Marathon Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Novel Oral AntiCoagulants (NOAC), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Novel Oral AntiCoagulants (NOAC), also provides the sales of main regions and countries. Of the upcoming market potential for Novel Oral AntiCoagulants (NOAC), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Novel Oral AntiCoagulants (NOAC) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Novel Oral AntiCoagulants (NOAC) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Novel Oral AntiCoagulants (NOAC) sales, projected growth trends, production technology, application and end-user industry.

Novel Oral AntiCoagulants (NOAC) Segment by Company

Armatheon
Aspen
Boehringer Ingelheim
Bristol-Myers Squibb
Cellceutix
Cosmo Pharmaceuticals
CSL Behring
Daiichi Sankyo
Marathon Pharmaceuticals
Ockham Biotech
Perosphere
AstraZeneca
Bayer
GSK
Johnson & Johnson
Sanofi
Eisai
Novel Oral AntiCoagulants (NOAC) Segment by Type

Direct Thrombin Inhibitors
Direct Factor Xa Inhibitors
Novel Oral AntiCoagulants (NOAC) Segment by Application

Hemodialysis
Deep Vein Thrombosis (DVT)
Acute Coronary Syndrome
Pulmonary Embolism
Others
Novel Oral AntiCoagulants (NOAC) Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Novel Oral AntiCoagulants (NOAC) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Novel Oral AntiCoagulants (NOAC) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Novel Oral AntiCoagulants (NOAC) significant trends, drivers, influence factors in global and regions.
6. To analyze Novel Oral AntiCoagulants (NOAC) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Oral AntiCoagulants (NOAC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Novel Oral AntiCoagulants (NOAC) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Oral AntiCoagulants (NOAC).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Novel Oral AntiCoagulants (NOAC) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Novel Oral AntiCoagulants (NOAC) industry.
Chapter 3: Detailed analysis of Novel Oral AntiCoagulants (NOAC) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Novel Oral AntiCoagulants (NOAC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Novel Oral AntiCoagulants (NOAC) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

205 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value (2020-2031)
1.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume (2020-2031)
1.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Novel Oral AntiCoagulants (NOAC) Market Dynamics
2.1 Novel Oral AntiCoagulants (NOAC) Industry Trends
2.2 Novel Oral AntiCoagulants (NOAC) Industry Drivers
2.3 Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges
2.4 Novel Oral AntiCoagulants (NOAC) Industry Restraints
3 Novel Oral AntiCoagulants (NOAC) Market by Company
3.1 Global Novel Oral AntiCoagulants (NOAC) Company Revenue Ranking in 2024
3.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Company (2020-2025)
3.3 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Company (2020-2025)
3.4 Global Novel Oral AntiCoagulants (NOAC) Average Price by Company (2020-2025)
3.5 Global Novel Oral AntiCoagulants (NOAC) Company Ranking (2023-2025)
3.6 Global Novel Oral AntiCoagulants (NOAC) Company Manufacturing Base and Headquarters
3.7 Global Novel Oral AntiCoagulants (NOAC) Company Product Type and Application
3.8 Global Novel Oral AntiCoagulants (NOAC) Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Novel Oral AntiCoagulants (NOAC) Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Novel Oral AntiCoagulants (NOAC) Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Novel Oral AntiCoagulants (NOAC) Market by Type
4.1 Novel Oral AntiCoagulants (NOAC) Type Introduction
4.1.1 Direct Thrombin Inhibitors
4.1.2 Direct Factor Xa Inhibitors
4.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type
4.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Type (2020-2031)
4.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Type (2020-2031)
4.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type
4.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Type (2020-2031)
4.3.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type (2020-2031)
5 Novel Oral AntiCoagulants (NOAC) Market by Application
5.1 Novel Oral AntiCoagulants (NOAC) Application Introduction
5.1.1 Hemodialysis
5.1.2 Deep Vein Thrombosis (DVT)
5.1.3 Acute Coronary Syndrome
5.1.4 Pulmonary Embolism
5.1.5 Others
5.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application
5.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Volume by Application (2020-2031)
5.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Volume Share by Application (2020-2031)
5.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application
5.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Application (2020-2031)
5.3.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application (2020-2031)
6 Novel Oral AntiCoagulants (NOAC) Regional Sales and Value Analysis
6.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2020-2031)
6.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2020-2025
6.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2026-2031)
6.3 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region (2020-2031)
6.4.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region: 2020-2025
6.4.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Region (2026-2031)
6.5 Global Novel Oral AntiCoagulants (NOAC) Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Novel Oral AntiCoagulants (NOAC) Sales Value (2020-2031)
6.6.2 North America Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Novel Oral AntiCoagulants (NOAC) Sales Value (2020-2031)
6.7.2 Europe Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Value (2020-2031)
6.8.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Novel Oral AntiCoagulants (NOAC) Sales Value (2020-2031)
6.9.2 South America Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales Value (2020-2031)
6.10.2 Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales Value Share by Country, 2024 VS 2031
7 Novel Oral AntiCoagulants (NOAC) Country-level Sales and Value Analysis
7.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Novel Oral AntiCoagulants (NOAC) Sales by Country (2020-2031)
7.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Country (2020-2025)
7.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Country (2026-2031)
7.4 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country (2020-2031)
7.4.1 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country (2020-2025)
7.4.2 Global Novel Oral AntiCoagulants (NOAC) Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.5.2 USA Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.6.2 Canada Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.8.2 Germany Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.9.2 France Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.9.3 France Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.11.2 Italy Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.12.2 Spain Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.13.2 Russia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.16.2 China Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.16.3 China Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.17.2 Japan Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.19.2 India Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.19.3 India Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.20.2 Australia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.24.2 Chile Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.26.2 Peru Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.28.2 Israel Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.29.2 UAE Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.31.2 Iran Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Novel Oral AntiCoagulants (NOAC) Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Armatheon
8.1.1 Armatheon Comapny Information
8.1.2 Armatheon Business Overview
8.1.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.1.4 Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.1.5 Armatheon Recent Developments
8.2 Aspen
8.2.1 Aspen Comapny Information
8.2.2 Aspen Business Overview
8.2.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.2.4 Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.2.5 Aspen Recent Developments
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim Comapny Information
8.3.2 Boehringer Ingelheim Business Overview
8.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.3.5 Boehringer Ingelheim Recent Developments
8.4 Bristol-Myers Squibb
8.4.1 Bristol-Myers Squibb Comapny Information
8.4.2 Bristol-Myers Squibb Business Overview
8.4.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.4.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.4.5 Bristol-Myers Squibb Recent Developments
8.5 Cellceutix
8.5.1 Cellceutix Comapny Information
8.5.2 Cellceutix Business Overview
8.5.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.5.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.5.5 Cellceutix Recent Developments
8.6 Cosmo Pharmaceuticals
8.6.1 Cosmo Pharmaceuticals Comapny Information
8.6.2 Cosmo Pharmaceuticals Business Overview
8.6.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.6.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.6.5 Cosmo Pharmaceuticals Recent Developments
8.7 CSL Behring
8.7.1 CSL Behring Comapny Information
8.7.2 CSL Behring Business Overview
8.7.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.7.4 CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.7.5 CSL Behring Recent Developments
8.8 Daiichi Sankyo
8.8.1 Daiichi Sankyo Comapny Information
8.8.2 Daiichi Sankyo Business Overview
8.8.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.8.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.8.5 Daiichi Sankyo Recent Developments
8.9 Marathon Pharmaceuticals
8.9.1 Marathon Pharmaceuticals Comapny Information
8.9.2 Marathon Pharmaceuticals Business Overview
8.9.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.9.4 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.9.5 Marathon Pharmaceuticals Recent Developments
8.10 Ockham Biotech
8.10.1 Ockham Biotech Comapny Information
8.10.2 Ockham Biotech Business Overview
8.10.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.10.4 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.10.5 Ockham Biotech Recent Developments
8.11 Perosphere
8.11.1 Perosphere Comapny Information
8.11.2 Perosphere Business Overview
8.11.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.11.4 Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.11.5 Perosphere Recent Developments
8.12 AstraZeneca
8.12.1 AstraZeneca Comapny Information
8.12.2 AstraZeneca Business Overview
8.12.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.12.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.12.5 AstraZeneca Recent Developments
8.13 Bayer
8.13.1 Bayer Comapny Information
8.13.2 Bayer Business Overview
8.13.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.13.4 Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.13.5 Bayer Recent Developments
8.14 GSK
8.14.1 GSK Comapny Information
8.14.2 GSK Business Overview
8.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.14.4 GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.14.5 GSK Recent Developments
8.15 Johnson & Johnson
8.15.1 Johnson & Johnson Comapny Information
8.15.2 Johnson & Johnson Business Overview
8.15.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.15.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.15.5 Johnson & Johnson Recent Developments
8.16 Sanofi
8.16.1 Sanofi Comapny Information
8.16.2 Sanofi Business Overview
8.16.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.16.4 Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.16.5 Sanofi Recent Developments
8.17 Eisai
8.17.1 Eisai Comapny Information
8.17.2 Eisai Business Overview
8.17.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Value and Gross Margin (2020-2025)
8.17.4 Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio
8.17.5 Eisai Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Novel Oral AntiCoagulants (NOAC) Value Chain Analysis
9.1.1 Novel Oral AntiCoagulants (NOAC) Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Novel Oral AntiCoagulants (NOAC) Sales Mode & Process
9.2 Novel Oral AntiCoagulants (NOAC) Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Novel Oral AntiCoagulants (NOAC) Distributors
9.2.3 Novel Oral AntiCoagulants (NOAC) Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.